Longeveron to Participate in the 149th Annual National Investment Banking Association Conference
29 août 2023 08h00 HE
|
Longeveron
MIAMI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for...
Longeveron Rights Offering Subscription Period Begins
22 août 2023 08h00 HE
|
Longeveron
MIAMI, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for...
Longeveron Rights Offering Declared Effective and Calendar Finalized
16 août 2023 09h13 HE
|
Longeveron
MIAMI, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023
14 août 2023 16h05 HE
|
Longeveron
MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,...
Longeveron Announces Pricing for Rights Offering and Expected Calendar
14 août 2023 08h00 HE
|
Longeveron
MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update
11 août 2023 07h30 HE
|
Longeveron
ELPIS II Study Exceeds 50% Enrollment Threshold for Phase 2 Trial of Lomecel-B™ in HLHS Top Line Results for CLEAR MIND Alzheimer’s disease Phase 2a Trial Anticipated by October 2023 Company...
Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome
11 août 2023 07h00 HE
|
Longeveron
Company Activates Additional Study Location to Expedite Enrollment Completion Key Opinion Leader Webinar Highlighting the Potential for Lomecel-B™ in the Treatment of HLHS to be held Wednesday,...
Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023
07 août 2023 08h00 HE
|
Longeveron
MIAMI, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
Longeveron Appoints Lisa Locklear as Chief Financial Officer
20 juil. 2023 08h00 HE
|
Longeveron
MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer
11 juil. 2023 08h00 HE
|
Longeveron
MIAMI, July 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...